All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Improving safety and efficacy of brentuximab vedotin, nivolumab, and AD for advanced stage cHL.
Featured
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke with Hun Lee, MD Anderson Cancer Centre, Texas, US. We asked about improving the safety and efficacy of combination treatment with brentuximab vedotin, nivolumab, adriamycin, and dacarbazine in patients with advanced-stage classic Hodgkin lymphoma.
Improving safety and efficacy of brentuximab vedotin, nivolumab, and AD for advanced stage cHL.
Lee discusses the long-term toxicities associated with prolonged chemotherapy treatment and findings from a study of combination treatment with brentuximab vedotin, nivolumab, adriamycin, and dacarbazine in patients with advanced-stage classic Hodgkin lymphoma. Lee then highlights the promising complete remission rates, progression-free survival, duration of remission, International Prognostic Scores, manageable safety profile, and overall response rates from a 12-month follow-up of the study.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox